Key Mesenchymal Precursor Cell Patent Granted in Japan

Key Mesenchymal Precursor Cell Patent Granted in Japan

Patent coverage provides for exclusive, long-term commercial rights in major
established healthcare market

NEW YORK and MELBOURNE, Australia, June 4, 2013 (GLOBE NEWSWIRE) --
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today
announced that it has been granted a key patent by the Japanese Patent Office.

Japanese patent number 5265190 provides Mesoblast with exclusive commercial
rights in Japan through to September 2025 to all compositions-of-matter and
uses of its Mesenchymal Precursor Cell (MPC) technology platform, irrespective
of the MPC tissue source, including bone marrow, adipose, placenta, umbilical
cord and dental pulp.

The granting of the Japanese patent follows the recent extension of
compositions-of-matter patents by the United States Patent and Trade Mark
Office to March 2029, and two key patents from the State Intellectual Property
Office of the People's Republic of China that provide commercial rights and
protection through to 2025.

The Japanese patent underpins Mesoblast's corporate strategy to protect
intellectual property covering its lead clinical products, to safeguard its
manufacturing processes and knowledge, and to extend the commercial reach of
its proprietary technologies in the world's major markets for regenerative
medicines.

About Mesoblast

Mesoblast Limited is a world leader in the development of biologic products
for the broad field of regenerative medicine. The Company's technologies
include its proprietary Mesenchymal Precursor Cell (MPC) technology platform
for bone marrow and adipose tissue derived products, Dental Pulp Stem Cells
(DPSCs) and expanded Hematopoietic Stem Cells (HSCs). Mesoblast's allogeneic
or 'off-the-shelf' regenerative medicine products focus on repair of damaged
issues and modulation of inflammatory responses in conditions with significant
unmet medical needs. The lead product candidates use its MPC platform in three
major and distinct areas - systemic inflammatory conditions, cardiovascular
diseases and orthopedic diseases of the spine. www.mesoblast.com

CONTACT: Julie Meldrum
         Global Head of Corporate Communications
         Mesoblast Limited
         T: +61 (0) 3 9639 6036
         E: julie.meldrum@mesoblast.com
 
Press spacebar to pause and continue. Press esc to stop.